Literature DB >> 15981019

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Rachael L Fleurence1, Cynthia P Iglesias, David J Torgerson.   

Abstract

Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. The objective of this study was to conduct a structured review of economic evaluations of interventions to prevent and treat osteoporosis. Articles were identified independently by two reviewers through searches on MEDLINE, the bibliographies of reviews and identified economic models, and expert opinion, using predefined inclusion and exclusion criteria. Data on country, type and level of interventions, type of fractures, interventions, study population and the authors' stated conclusions were extracted. Forty-two relevant studies were identified. The majority of studies (71%) were conducted in Sweden, the UK and the US. The main interventions investigated were hormone replacement therapy (27%), bisphosphonates (17%) and combinations of vitamin D and calcium (16%). In 38% of studies, hip fracture was the sole fracture outcome. Eighty-eight percent (88%) of studies investigated female populations only. A relatively large number of economic evaluations were identified in the field of osteoporosis. Major changes have recently occurred in the treatment of this disease, following the publication of the results of the Women's Health Initiative trial. Methodological developments in economic evaluations, such as the use of probabilistic sensitivity analysis and cost-effectiveness acceptability curves, have also taken place. Such changes are reflected in the studies that were reviewed. The development of economic models should be an iterative process that incorporates new information, whether clinical or methodological, as it becomes available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981019     DOI: 10.1007/s00198-005-1943-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  67 in total

1.  Effect and offset of effect of treatments for hip fracture on health outcomes.

Authors:  B Jonsson; J Kanis; A Dawson; A Oden; O Johnell
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  An economic analysis of external hip protector use in ambulatory nursing facility residents.

Authors:  Cathleen S Colón-Emeric; Santanu K Datta; David B Matchar
Journal:  Age Ageing       Date:  2003-01       Impact factor: 10.668

3.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

4.  Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy.

Authors:  P Visentin; R Ciravegna; F Fabris
Journal:  Maturitas       Date:  1997-04       Impact factor: 4.342

5.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.

Authors:  A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

6.  The cost utility of bisphosphonate treatment in established osteoporosis.

Authors:  C P Iglesias; D J Torgerson; A Bearne; U Bose
Journal:  QJM       Date:  2002-05

7.  Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.

Authors:  M D Stevenson; J Oakley; J B Chilcott
Journal:  Med Decis Making       Date:  2004 Jan-Feb       Impact factor: 2.583

8.  Randomized controlled trial of hip protectors among women living in the community.

Authors:  Yvonne F Birks; Jill Porthouse; Caroline Addie; Karen Loughney; Lucy Saxon; Mike Baverstock; Roger M Francis; David M Reid; Ian Watt; David J Torgerson
Journal:  Osteoporos Int       Date:  2004-03-03       Impact factor: 4.507

9.  A comparison of the effectiveness and cost of treatment for vertebral fractures in women.

Authors:  R M Francis; F H Anderson; D J Torgerson
Journal:  Br J Rheumatol       Date:  1995-12

10.  Cost-effectiveness of hormone replacement therapy in the menopause.

Authors:  M C Weinstein; I Schiff
Journal:  Obstet Gynecol Surv       Date:  1983-08       Impact factor: 2.347

View more
  21 in total

1.  Bivariate linkage study of proximal hip geometry and body size indices: the Framingham study.

Authors:  D Karasik; J Dupuis; L A Cupples; T J Beck; M C Mahaney; L M Havill; D P Kiel; S Demissie
Journal:  Calcif Tissue Int       Date:  2007-08-03       Impact factor: 4.333

Review 2.  A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.

Authors:  Mickaël Hiligsmann; Silvia M Evers; Wafa Ben Sedrine; John A Kanis; Bram Ramaekers; Jean-Yves Reginster; Stuart Silverman; Caroline E Wyers; Annelies Boonen
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

3.  Polymorphisms in the endothelial nitric oxide synthase gene and bone density/ultrasound and geometry in humans.

Authors:  K Cho; S Demissie; J Dupuis; L A Cupples; S Kathiresan; T J Beck; D Karasik; D P Kiel
Journal:  Bone       Date:  2007-09-29       Impact factor: 4.398

4.  Lasofoxifene: Evidence of its therapeutic value in osteoporosis.

Authors:  Luigi Gennari; Daniela Merlotti; Vincenzo De Paola; Ranuccio Nuti
Journal:  Core Evid       Date:  2010-06-15

5.  Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.

Authors:  B McGowan; K Bennett; M C Casey; J Doherty; C Silke; B Whelan
Journal:  Ir J Med Sci       Date:  2013-03-13       Impact factor: 1.568

6.  The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.

Authors:  N Zethraeus; O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

Review 7.  The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; Jeanene M Johnson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  The health-related quality of life and cost implications of falls in elderly women.

Authors:  C P Iglesias; A Manca; D J Torgerson
Journal:  Osteoporos Int       Date:  2008-10-10       Impact factor: 4.507

9.  [Economic concepts for measuring the costs of illness of osteoporosis: an international comparison].

Authors:  K Viktoria Stein; Thomas Dorner; Kitty Lawrence; Michael Kunze; Anita Rieder
Journal:  Wien Med Wochenschr       Date:  2009-05

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.